Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
10.1007/s00429-014-0714-z Summary Keywords GLP-1, obesity, diabetes, CNS, insulin Citation Heppner KM and Perez-Tilve D (2015) GLP-1 based therapeutics: simultaneously combating T2DM and obesity
A researcher on a 4mg weekly protocol who switches to microdosing might inject approximately 1.3mg three times per week, Monday, Wednesday, and Friday
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Weekly retatrutide injections (1 mg12 mg) resulted in weight reductions of 7.217.5% at 24 weeks and 8.724.2% at 48 weeks in subjects with overweight or obesity (without T2DM) in a phase II, double-blind, randomized, placebo-controlled [125]
Endocrinologist Timothy Garvey at the University of Alabama at Birmingham calls this era "on par with the discovery of insulin, the discovery of penicillin, the polio vaccine." That comparison boosts GLP-1s to landmark status in public consciousness
